GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (TSE:4523) » Definitions » Short Interest

Eisai Co (TSE:4523) Short Interest


View and export this data going back to 1961. Start your Free Trial

What is Eisai Co Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Eisai Co's Short Interest

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eisai Co's Short Interest Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Short Interest distribution charts can be found below:

* The bar in red indicates where Eisai Co's Short Interest falls into.


Eisai Co (TSE:4523) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (TSE:4523) » Definitions » Short Interest
Comparable Companies
TSE:4507 TSE:4581 TSE:4516 TSE:4530 TSE:4540 TSE:4887 TSE:4506 TSE:4547 TSE:4553 TSE:4521 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA VTRS NBIX XSWX:SDZ SZSE:000538
Traded in Other Exchanges
ESAIY:USA ESALF:USA EII:Germany
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Website
http://www.eisai.co.jp
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co (TSE:4523) Headlines

No Headlines